GAIN THERAPEUTICS INC (GANX:NASDAQ)
$1.95 -0.07 (-3.4653%)
Analysed GAIN THERAPEUTICS INC (GANX:NASDAQ) News Sources
Gain Therapeutics to Present at the 38th Annual ROTH Conference
19-03-2026
yahoo.com
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference
24-03-2026
marketbeat.com
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
26-03-2026
yahoo.com
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
24-04-2026
yahoo.com
3 US Biotechs Developing Parkinson’s Therapies
05-05-2026
yahoo.com
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
11-05-2026
yahoo.com
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss
11-05-2026
advfn.com
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
22-05-2026
yahoo.com
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
26-05-2026
yahoo.com
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
27-05-2026
yahoo.com
What is the current price of GAIN THERAPEUTICS INC (GANX:NASDAQ)?
The current price of GAIN THERAPEUTICS INC (GANX:NASDAQ) is $1.95.
GAIN THERAPEUTICS INC (GANX:NASDAQ) absolute price change since previous trading day?
The absolute price change of GAIN THERAPEUTICS INC (GANX:NASDAQ) since the previous trading day is $-0.07.
GAIN THERAPEUTICS INC (GANX:NASDAQ) percentage price change since previous trading day?
The percentage price change of GAIN THERAPEUTICS INC (GANX:NASDAQ) since the previous trading day is -3.4653%.
What is the most recent average sentiment score for GAIN THERAPEUTICS INC (GANX:NASDAQ)?
The most recent average sentiment score for GAIN THERAPEUTICS INC (GANX:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for GAIN THERAPEUTICS INC (GANX:NASDAQ)?
The most recent sentiment for GAIN THERAPEUTICS INC (GANX:NASDAQ) is .
SEC-8K** Filing Available For GAIN THERAPEUTICS INC (GANX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.